Cargando…
Association between effector-type regulatory T cells and immune checkpoint expression on CD8(+) T cells in malignant ascites from epithelial ovarian cancer
BACKGROUND: Regulatory T cells (Tregs) play an important role in the antitumor immune response in epithelial ovarian cancer (EOC). To understand the immune-inhibitory networks of EOC, we addressed the association between Tregs and immune checkpoint expression on T cells in the tumor microenvironment...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9026673/ https://www.ncbi.nlm.nih.gov/pubmed/35449092 http://dx.doi.org/10.1186/s12885-022-09534-z |
_version_ | 1784691171204792320 |
---|---|
author | Sato, Sho Matsushita, Hirokazu Shintani, Daisuke Kobayashi, Yukari Fujieda, Nao Yabuno, Akira Nishikawa, Tadaaki Fujiwara, Keiichi Kakimi, Kazuhiro Hasegawa, Kosei |
author_facet | Sato, Sho Matsushita, Hirokazu Shintani, Daisuke Kobayashi, Yukari Fujieda, Nao Yabuno, Akira Nishikawa, Tadaaki Fujiwara, Keiichi Kakimi, Kazuhiro Hasegawa, Kosei |
author_sort | Sato, Sho |
collection | PubMed |
description | BACKGROUND: Regulatory T cells (Tregs) play an important role in the antitumor immune response in epithelial ovarian cancer (EOC). To understand the immune-inhibitory networks of EOC, we addressed the association between Tregs and immune checkpoint expression on T cells in the tumor microenvironment of EOC. METHODS: A total of 41 patients with stage IIIC and IV EOC were included in the analysis. We harvested cells from malignant ascites and investigated them using multi-color flow cytometry. We categorized the Tregs into 3 groups: effector-type Tregs, naïve Tregs and non-Tregs, based on the expression patterns of CD45RA and Foxp3 in CD4(+) T cells. Furthermore, the relationships between the expression of various immune checkpoint molecules, such as PD-1, on CD8(+) T cells and each of the Treg subtypes was also evaluated. RESULTS: The median frequency of naïve Tregs, effector-type Tregs and non-Tregs were 0.2% (0–0.8), 2.0% (0–11.4) and 1.5% (0.1–6.3) in CD4(+) T cells of malignant ascites from EOC patients, respectively. A high frequency of effector-type Tregs was associated with high-grade serous carcinoma compared with the other histotypes. Patients with higher proportions of effector-type Tregs showed a trend towards increased progression-free survival. We also demonstrated a correlation between a higher proportion of effector-type Tregs and increased PD-1 expression on CD8(+) T cells. In addition, C–C chemokine receptor 4 expression was also observed in effector-type Tregs. CONCLUSION: These data suggest that multiple immune-inhibitory networks exist in malignant ascites from EOC patients, suggesting an approach towards combinational immunotherapies for advanced EOC patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-022-09534-z. |
format | Online Article Text |
id | pubmed-9026673 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-90266732022-04-23 Association between effector-type regulatory T cells and immune checkpoint expression on CD8(+) T cells in malignant ascites from epithelial ovarian cancer Sato, Sho Matsushita, Hirokazu Shintani, Daisuke Kobayashi, Yukari Fujieda, Nao Yabuno, Akira Nishikawa, Tadaaki Fujiwara, Keiichi Kakimi, Kazuhiro Hasegawa, Kosei BMC Cancer Research BACKGROUND: Regulatory T cells (Tregs) play an important role in the antitumor immune response in epithelial ovarian cancer (EOC). To understand the immune-inhibitory networks of EOC, we addressed the association between Tregs and immune checkpoint expression on T cells in the tumor microenvironment of EOC. METHODS: A total of 41 patients with stage IIIC and IV EOC were included in the analysis. We harvested cells from malignant ascites and investigated them using multi-color flow cytometry. We categorized the Tregs into 3 groups: effector-type Tregs, naïve Tregs and non-Tregs, based on the expression patterns of CD45RA and Foxp3 in CD4(+) T cells. Furthermore, the relationships between the expression of various immune checkpoint molecules, such as PD-1, on CD8(+) T cells and each of the Treg subtypes was also evaluated. RESULTS: The median frequency of naïve Tregs, effector-type Tregs and non-Tregs were 0.2% (0–0.8), 2.0% (0–11.4) and 1.5% (0.1–6.3) in CD4(+) T cells of malignant ascites from EOC patients, respectively. A high frequency of effector-type Tregs was associated with high-grade serous carcinoma compared with the other histotypes. Patients with higher proportions of effector-type Tregs showed a trend towards increased progression-free survival. We also demonstrated a correlation between a higher proportion of effector-type Tregs and increased PD-1 expression on CD8(+) T cells. In addition, C–C chemokine receptor 4 expression was also observed in effector-type Tregs. CONCLUSION: These data suggest that multiple immune-inhibitory networks exist in malignant ascites from EOC patients, suggesting an approach towards combinational immunotherapies for advanced EOC patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-022-09534-z. BioMed Central 2022-04-21 /pmc/articles/PMC9026673/ /pubmed/35449092 http://dx.doi.org/10.1186/s12885-022-09534-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visithttp://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Sato, Sho Matsushita, Hirokazu Shintani, Daisuke Kobayashi, Yukari Fujieda, Nao Yabuno, Akira Nishikawa, Tadaaki Fujiwara, Keiichi Kakimi, Kazuhiro Hasegawa, Kosei Association between effector-type regulatory T cells and immune checkpoint expression on CD8(+) T cells in malignant ascites from epithelial ovarian cancer |
title | Association between effector-type regulatory T cells and immune checkpoint expression on CD8(+) T cells in malignant ascites from epithelial ovarian cancer |
title_full | Association between effector-type regulatory T cells and immune checkpoint expression on CD8(+) T cells in malignant ascites from epithelial ovarian cancer |
title_fullStr | Association between effector-type regulatory T cells and immune checkpoint expression on CD8(+) T cells in malignant ascites from epithelial ovarian cancer |
title_full_unstemmed | Association between effector-type regulatory T cells and immune checkpoint expression on CD8(+) T cells in malignant ascites from epithelial ovarian cancer |
title_short | Association between effector-type regulatory T cells and immune checkpoint expression on CD8(+) T cells in malignant ascites from epithelial ovarian cancer |
title_sort | association between effector-type regulatory t cells and immune checkpoint expression on cd8(+) t cells in malignant ascites from epithelial ovarian cancer |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9026673/ https://www.ncbi.nlm.nih.gov/pubmed/35449092 http://dx.doi.org/10.1186/s12885-022-09534-z |
work_keys_str_mv | AT satosho associationbetweeneffectortyperegulatorytcellsandimmunecheckpointexpressiononcd8tcellsinmalignantascitesfromepithelialovariancancer AT matsushitahirokazu associationbetweeneffectortyperegulatorytcellsandimmunecheckpointexpressiononcd8tcellsinmalignantascitesfromepithelialovariancancer AT shintanidaisuke associationbetweeneffectortyperegulatorytcellsandimmunecheckpointexpressiononcd8tcellsinmalignantascitesfromepithelialovariancancer AT kobayashiyukari associationbetweeneffectortyperegulatorytcellsandimmunecheckpointexpressiononcd8tcellsinmalignantascitesfromepithelialovariancancer AT fujiedanao associationbetweeneffectortyperegulatorytcellsandimmunecheckpointexpressiononcd8tcellsinmalignantascitesfromepithelialovariancancer AT yabunoakira associationbetweeneffectortyperegulatorytcellsandimmunecheckpointexpressiononcd8tcellsinmalignantascitesfromepithelialovariancancer AT nishikawatadaaki associationbetweeneffectortyperegulatorytcellsandimmunecheckpointexpressiononcd8tcellsinmalignantascitesfromepithelialovariancancer AT fujiwarakeiichi associationbetweeneffectortyperegulatorytcellsandimmunecheckpointexpressiononcd8tcellsinmalignantascitesfromepithelialovariancancer AT kakimikazuhiro associationbetweeneffectortyperegulatorytcellsandimmunecheckpointexpressiononcd8tcellsinmalignantascitesfromepithelialovariancancer AT hasegawakosei associationbetweeneffectortyperegulatorytcellsandimmunecheckpointexpressiononcd8tcellsinmalignantascitesfromepithelialovariancancer |